Skip to main content

Sirnaomics Partners with Chinese Pharma on Wound-Healing Drug

Premium

Sirnaomics said this week that it has signed a deal with an undisclosed Chinese pharmaceutical company to co-develop an siRNA-based drug for scarless wound healing.

The drug, STP705, uses a polymeric nanoparticle to enhance topical delivery of siRNAs targeting the TGF-beta 1 and Cox-2 genes to open wounds, Sirnaomics said.

The new alliance "provides financial resources and local capabilities allowing acceleration through the clinical study and regulatory process in China," the company added.

The arrangement, which includes "licensing, funding, and market-sharing structures," is limited to the greater China area, including Hong Kong, Macau, and Taiwan. Additional terms were not disclosed.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.